Abstract
Introduction: In this review article the safety and efficacy of of Lifitegrast™ in the management of dry eye disease is described.
 Methods: Search was carried out using related search terms in data bases like pubmed and related articles were referred.
 Result: A larger reduction in Eye dryness Score (EDS) was seen with Lifitegrast™.
 Conclusion: Lifitegrast™ ophthalmic solution 5% provides a new option for the treatment of dry eyes.
Highlights
In this review article the safety and efficacy of of LifitegrastTM in the management of dry eye disease is described
It belongs to lymphocyte associated antigen-1 (LFA-1) antagonist
A cell surface protein found on leucocytes which is an integrin lymphocyte function-associated antigen-1 (LFA-1)
Summary
A cell surface protein found on leucocytes which is an integrin lymphocyte function-associated antigen-1 (LFA-1). LifitegrastTM binds to LFA-1 and blocks the interaction of LFA-1 with its ligand ICAM-1(intracellular adhesion molecule-1). Interaction of LFA-1/ICAM-1 leads to formation of an immunological synapse resulting in T-cell activation and migration to target tissues [1]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
